Newer Horizon of Mesenchymal Stem Cell–Based Therapy in the Management of SARS-CoV-2–Associated Mucormycosis: A Safe Hope for Future Medicine

SARS-CoV-2–infected patients are reported to show immunocompromised behavior that gives rise to a wide variety of complications due to impaired innate immune response, cytokine storm, and thrombo-inflammation. Prolonged use of steroids, diabetes mellitus, and diabetic ketoacidosis (DKA) are some of the factors responsible for the growth of Mucorales in such immunocompromised patients and, thus, can lead to a life-threatening condition referred to as mucormycosis. Therefore, an early diagnosis and cell-based management cosis is the need of the hour to help affected patients overcome this severe condition. In addition, extended exposure to antifungal drugs/therapeutics is found to initiate hormonal and neurological complications. More recently, mesenchymal stem cells (MSCs) have been used to exhibit immunomodulatory function and proven to be beneficial in a clinical cell-based regenerative approach. The immunomodulation ability of MSCs in mucormycosis patient boosts the immunity by the release of chemotactic proteins. MSC-based therapy in mucormycosis along with the combination of short-term antifungal drugs can be utilized as a prospective approach for mucormycosis treatment with promising outcomes. However, preclinical and in mucormyIn mucormycosis, the hyphae of clinical trials are needed to establish the precise mechanism of MSCs in mucormycosis treatment.

Abstract licence: CC BY

1. 63.

   Stem Cell-Derived Extracellular Vesicles and Immune-Modulation · 2016

2. 68.

   Molecular mechanisms of mucormycosis—The bitter and the sweet · 2017

3. 75.

   Global Epidemiology of Mucormycosis · 2019

4. 82.

   Immune modulation by mesenchymal stem cells · 2019

5. 83.

   Mesenchymal stem cell perspective: cell biology to clinical progress · 2019

6. 84.
   Corrected

   A new coronavirus associated with human respiratory disease in China · 2020

7. 87.

   Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells · 2020

8. 90.

   Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020 · 2020

9. 91.

   Rhino-Orbital Mucormycosis Associated With COVID-19 · 2020

10. 96.

    Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series · 2021

11. 98.

    Epidemiology of Mucormycosis in India · 2021

92 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.